Pregabalin Capsule
Product Images NDC 71335-1762

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-1762). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351762)

Label for Pregabalin 25 mg (CV) capsules by Bryant Ranch Prepack, packed in Burbank, CA. The label includes a comparison to Lyrica 25 mg capsules, manufactured by Alkem Laboratories Ltd. Storage instructions indicate keeping at 20°-25°C (68°-77°F) and out of reach of children. The package size is 30 capsules with NDC 71335-1762-1 and includes a barcode and lot number 1523487.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Equation 1)

A text panel showing a mathematical formula for calculating creatinine clearance (CLCr). The equation adjusts for age, weight, serum creatinine, and includes a factor for female patients.*

FDA Label Image

Study Dpn 1 (Pregabalin Image 1)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin capsules. Four lines compare Pregabalin 300 mg and 600 mg taken three times daily, Pregabalin 150 mg taken three times daily, and placebo, showing trends in pain improvement percentages across these dosing groups.*

FDA Label Image

Study Sci 1 (Pregabalin Image 10)

A line graph showing the percent of subjects improved versus percent improved from baseline to week 12 BOCF. It compares two lines labeled Pregabalin and Placebo, with percent improved on the vertical axis and percent improved from baseline to week 12 BOCF on the horizontal axis.*

FDA Label Image

Pain Intensity-study Sci 2 (Pregabalin Image 11)

A line graph showing the percentage of subjects improved from baseline to Week 16 over various percent improvement intervals. Two lines compare Pregabalin and Placebo, with Pregabalin consistently showing a higher percentage of improvement than Placebo across the range.*

FDA Label Image

Study Dpn 2 (Pregabalin Image 2)

A line chart showing the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 100 mg three times a day to placebo. The y-axis represents the percent of patients improved, and the x-axis represents the percent improvement in pain. Two lines indicate the treatment groups with vertical reference lines at specific improvement percentages.*

FDA Label Image

Study Phn 1 (Pregabalin Image 3)

A line chart showing percent of patients improved versus percent improvement in pain from baseline. The chart compares Pregabalin at dosages of 75 mg, 150 mg, and 300 mg taken twice a day against placebo, illustrating varying levels of patient improvement over different pain reduction thresholds.*

FDA Label Image

Study Phn 2 (Pregabalin Image 4)

A line graph showing the percent of patients improved plotted against the percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, illustrating differences in pain improvement among them.*

FDA Label Image

Study Phn 3 (Pregabalin Image 5)

A line graph depicting percent improvement in pain from baseline on the x-axis against percent of patients improved on the y-axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, showing patient response distribution over a range of pain improvements.*

FDA Label Image

Epilepsy Study (Pregabalin Image 6)

A bar graph showing responder rates (%) for two studies, labeled Study E1 and Study E3. The graph displays responder rates for different dose groups including placebo and varying doses of Pregabalin. The y-axis represents responder rate percentages, while the x-axis shows treatment groups, with sample sizes indicated below each group.*

FDA Label Image

Studies E1, E2, And E3 (Pregabalin Image 7)

A line graph depicting seizure reduction as median percentage change from baseline versus daily dose in mg for Pregabalin. It shows data points from four studies (E1BD, E2TID, E3BD, E3TID) with increasing dose on the x-axis and seizure reduction on the y-axis, annotated with p-values indicating statistical significance (all p ≤ 0.0001 except one at p = 0.0007). Placebo dose is represented at zero.*

FDA Label Image

Fibromyalgia Study F1 (Pregabalin Image 8)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at daily doses of 300 mg, 450 mg, and 600 mg compared to placebo. The graph shows four lines indicating patient response rates across different levels of pain improvement.*

FDA Label Image

Fibromyalgia Study F2 (Pregabalin Image 9)

A line graph depicting the estimated percentage of subjects without LTFU (Loss to Follow-Up) over a 180-day period for Pregabalin versus Placebo. The y-axis shows the estimated percentage of subjects without LTFU from 0% to 100%, and the x-axis shows days from 0 to 180. Two lines represent Pregabalin and Placebo, with Pregabalin consistently maintaining a higher percentage of subjects without LTFU throughout the period.*

FDA Label Image

Pregabalin Structure (Pregabalin Srtuc 1)

Chemical structure of pregabalin, showing its molecular framework with functional groups including a carboxylic acid (CO2H) and an amine (NH2). This diagram represents the structure of the active ingredient pregabalin in the product.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.